BioCentury
ARTICLE | Company News

Theravance, GlaxoSmithKline sales and marketing update

May 5, 2014 7:00 AM UTC

The partners launched in the U.S. Anoro Ellipta umeclidinium bromide/vilanterol as a once-daily maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD). The wholesale acquisition cost (WAC) for a disposable inhaler with 60 uses is $280.95, and the WAC for a disposable inhaler with 14 uses is $78.76. The launch triggered a $30 million milestone payment to GSK from Theravance under a 2002 deal to develop compounds to treat asthma and COPD, including Anoro Ellipta. The launch also triggered a £2 million ($3.4 million) milestone payment to Vectura Group plc (LSE:VEC, Chippenham, U.K.) from GSK under a 2010 deal granting the pharma rights to certain of Vectura's dry powder formulation patents. Vectura said all of the £10 million ($16.8 million) milestones in the deal have been triggered. The product is a fixed-dose inhaled dry powder formulation of a long-acting muscarinic antagonist (LAMA) and a long-acting adrenergic receptor beta 2 agonist (LABA). ...